Diagnostics for the Real World (DRW), a pioneer in rapid molecular diagnostics, today announces the launch of the SAMBA III Instrument System – its most advanced point-of-care molecular platform to date. Building on more than two decades of innovation, SAMBA III has been designed to deliver laboratory-quality molecular results in approximately 30 minutes with minimal hands-on time, enabling faster clinical decision-making closer to the patient.

The launch represents a significant milestone for DRW, whose mission has always been to make accurate molecular diagnostics accessible wherever they are needed most. From transforming HIV testing in resource-limited settings to supporting NHS hospitals throughout the COVID-19 pandemic, the SAMBA platform has demonstrated the value of rapid, decentralised diagnostics in improving patient care.

SAMBA III takes this vision further. The fully integrated platform combines enhanced performance, increased flexibility and an expanding menu of multiplex assays spanning respiratory infections, gastrointestinal pathogens and sexually transmitted infections. Designed for near-patient settings, the system enables healthcare professionals to deliver timely diagnoses without relying on central laboratory workflows.

“With SAMBA III, we are entering an exciting new chapter for molecular diagnostics,” said Dr Helen Lee, Founder and CEO of DRW. “Healthcare systems around the world continue to face increasing pressure from infectious diseases, rising patient demand and limited laboratory capacity. Our goal has always been to develop technology that works in the real world—technology that is simple to use, highly accurate and capable of delivering rapid answers when clinical decisions matter most.

SAMBA III reflects everything we have learned over the past twenty years. It is faster, more flexible and designed to support a growing range of infectious disease applications.”